Significant attention has been directed toward IDH1/2 mutations because these markers play a fundamental role in the classification of gliomas according to the revised 2016 WHO CNS guidelines (Eckel-Passow et al., 2015; Louis et al., 2016). Here, IDH1 is linked to central nervous system cancer.